J Gynecol Oncol.
2020 Nov;31(6):e95. 10.3802/jgo.2020.31.e95.
Olaparib and bevacizumab in frontline maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
- Affiliations
-
- 1Brazilian National Cancer Institute and Grupo Oncoclínicas, Rio de Janeiro, Brazil
- KMID: 2512073
- DOI: http://doi.org/10.3802/jgo.2020.31.e95
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
- Targeted therapy and immunotherapy in ovarian cancer
- A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
- Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
- Targeted therapy of ovarian cancer including immune check point inhibitor
